RT Journal Article
SR Electronic
T1 Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.09.21252401
DO 10.1101/2021.03.09.21252401
A1 Santano, Rebeca
A1 Barrios, Diana
A1 Crispi, Fàtima
A1 Crovetto, Francesca
A1 Vidal, Marta
A1 Chi, Jordi
A1 Izquierdo, Luis
A1 Gratacós, Eduard
A1 Moncunill, Gemma
A1 Dobaño, Carlota
YR 2021
UL http://medrxiv.org/content/early/2021/03/10/2021.03.09.21252401.abstract
AB Serological diagnostic of the severe respiratory distress syndrome coronavirus 2 (SARS-CoV-2) is a valuable tool for the determination of immunity and surveillance of exposure to the virus. In the context of an ongoing pandemic, it is essential to externally validate widely used tests to assure correct diagnostics and epidemiological estimations. We evaluated the performance of the COVID-19 ELISA IgG and IgM/A (Vircell, S.L.) against a highly specific and sensitive in-house Luminex immunoassay in a set of samples from pregnant women and cord blood. The agreement between both assays was moderate to high for IgG but low for IgM/A. Considering seropositivity by either IgG and/or IgM/A, the technical performance of the ELISA was highly imbalanced, with 96% sensitivity at the expense of 22% specificity. As for the clinical performance, the negative predictive value reached 87% while the positive predictive value was 51%. Our results stress the need for highly specific and sensitive assays and external validation of diagnostic tests with different sets of samples to avoid the clinical, epidemiological and personal disturbances derived from serological misdiagnosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by the KidsCorona Child and Mother COVID-19 OpenData and Biobank Initiative from Hospital Sant Joan de Deu (Stavros Niarchos Foundation, Santander Foundation and others), LaCaixa Foundation, Sant Pau Research Institute, ISGlobal and Fundacio Privada Daniel Bravo Andreu, Barcelona, Spain. Development of SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C. L. I. work was supported by PID2019-110810RB-I00 grant from the Spanish Ministry of Science & Innovation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1. Full names / affiliations of all ethics committees / Institutional Review Boards that ruled on ethics of your study. - Ethical Committee of Hospital Clinic (HCB-2020-0434) - Ethical Committee of Hospital Sant Joan de Deu (PIC-56-20) - Ethical Committee of Hospital Sant Pau (IIBSP-COV-2020-38) 2. Decision made, i.e. whether ethical approval was given or waived. All three Ethical Committees already approved the study. All participants signed a written consent form.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article. Raw data of this study are available from the corresponding author R.S. on request.